NNVC earnings analysis
What we found in NNVC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
NanoViricides, Inc. continues to experience significant operating losses as it advances its antiviral drug NV-387, which just completed a Phase I clinical trial. The balance sheet shows improved cash reserves, yet management signals ongoing financial challenges and reliance on further capital raises to sustain operations. There remain doubts regarding the company’s ability to continue as a going concern without further financing.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improved Cash Position
- Cash and cash equivalents increased to $3,213,256 from $1,558,564 as of June 30, 2025.
- Reduced Operating Loss
- Net loss for Q3 2026 was $(1,989,333) or $(0.09) per share, improved from $(2,216,783) or $(0.14) per share for Q3 2025.
- Orphan Drug Designation Granted
- FDA granted Orphan Drug Designation for NV-387 as a treatment for Measles on April 27, 2026.
- Sustained R&D Focus
- Continued investment in R&D resulted in $1,285,942 spent for Q3 2026, up slightly from the prior year.
- Corporate Financing
- Raised approximately $7.3 million from equity offerings over the past nine months.
- Clinical Trial Progress
- Phase II clinical trial for MPox is set to begin soon in DRC, focusing on NV-387's efficacy.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial Doubt About Going Concern
- Management notes that current cash reserves and credit lines will be insufficient to fund operations for the next 12 months.
- Continued Operating Losses
- Accumulated deficit stands at approximately $154.8 million with no revenue expected in the foreseeable future.
- High Dependency on Financing
- Reliance on capital raises creates uncertainty about the company's long-term financial stability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.09
What they said about what is next.
Management anticipates progress with further clinical trials but does not provide numeric guidance on revenue or EPS.
The filing reads worse than the one before it.
What came before.
- 10-Q · February 17, 2026
- NanoViricides remains a pre-revenue clinical-stage company. For the quarter ended December 31, 2025 the company reported a net loss of $2,220,719 (EPS -$0.11) and operating expenses of $2,233,174; cash increased to…
- 10-Q · November 14, 2025
- NanoViricides reported a narrower quarterly net loss of $1,785,058 (EPS -$0.10) for the three months ended September 30, 2025 versus a net loss of $3,126,811 (EPS -$0.23) in the year‑ago quarter. The company remains…
- 10-Q · May 15, 2025
- NanoViricides reported a quarterly net loss of $2,216,783 (EPS -$0.14) for the three months ended March 31, 2025 versus a net loss of $1,854,476 (EPS -$0.16) in the year‑ago quarter; the company still reports no…
- 10-Q · November 14, 2024
- NanoViricides reported a larger quarterly loss and continued cash burn with no revenues. For the three months ended September 30, 2024 the company recorded a net loss of $3,126,811 (EPS -$0.23) and used $2,594,863 of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NNVC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever